Loading the company…
Loading the company…
㈜데어리젠
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-10-11 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gangwon, founded in 2002. Industry: Food & Consumer Goods. Revenue for 2025 was ₩68.3bn. It has 182 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2023-02-14 · newest first
본 발명은, LPS(lipopolysaccharide)가 투여된 마우스에서 IL-6 등의 염증성 사이토카인이나 COX-2 등 염증 관련 인자의 발현을 억제하고 마우스 생존율을 높이며 또 혈액의 백혈구, 호중구 등의 수를 감소시키는 활성을 가진, 락토바실러스 플란타럼 배양물 등이 혼합된 치즈를 이용한 항염증용 조성물을 개시한다.
본 발명은 수수 추출물을 이용한 유산균 발효유의 제조방법을 개시한다. 본 발명의 방법에 의하여 얻어진 유산균 발효유는 색소로서 수수 추출물을 함유함으로써 제조시 의도한 색상이 보관·유통 과정에서의 pH, 온도 변화 등에도 그대로 유지되고 더불어 향미 등의 기호도도 향상된 효과를 가진다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 62.3 | 68.3 |
| Cost of sales | 53.2 | 58.8 |
| Gross profit (loss) | 9.2 | 9.5 |
| Selling, general and administrative expenses | 6.4 | 6.8 |
| Operating income (loss) | 2.7 | 2.7 |
| Non-operating income | 0.3 | 0.3 |
| Other gains | 0.2 | 0.1 |
| Finance income | 0.0 | 0.0 |
| Other | 0.1 | 0.2 |
| Non-operating expenses | 1.5 | 1.6 |
| Other losses | 0.1 | 0.1 |
| Finance costs | 1.0 | 1.4 |
| Other | 0.5 | 0.1 |
| Profit (loss) before tax | 1.5 | 1.5 |
| Income tax expense | 0.1 | 0.0 |
| Net income (loss) | 1.4 | 1.4 |
Revenue ₩68.3bn, up 9.6% YoY.
Operating margin 4.0% (prior 4.4%).
Net income ₩1.4bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-05